Key result
Risk-weighted apoB reclassifies ~60% of patients by ≥10 percentile points vs conventional apoB.
Its licence doesn't allow us to show a copy here.
Why the study?
Apolipoprotein B assumes equal cardiovascular risk across all apoB-containing lipoproteins, but Mendelian randomization suggests TRLs and Lp(a) are more atherogenic per particle, motivating evaluation of risk-weighted apoB for better risk assessment.
Does risk-weighted apoB (RW-apoB) reclassify atherogenic burden compared to measured apoB in adults with elevated Lp(a)?
Observational (n=1,861)
Yes
Does risk-weighted apoB (RW-apoB) reclassify atherogenic burden compared to measured apoB in adults with elevated Lp(a)?
Conventional apoB substantially underestimates the atherogenic burden in patients with elevated Lp(a), highlighting the utility of risk-weighted apoB for more accurate cardiovascular risk assessment.
BACKGROUND AND AIMS Apolipoprotein B (apoB) is the preferred marker of atherogenic particle burden, but it assumes that all apoB-containing lipoproteins confer the same cardiovascular risk. Mendelian randomization studies suggest that triglyceride-rich lipoproteins (TRLs) and lipoprotein(a) [Lp(a)] are more atherogenic per apoB particle than LDL. Risk-weighted apoB (RW-apoB) captures these differences in a single metric. We assessed the reclassification produced by RW-apoB versus measured apoB in the GAELp(a) registry, a real-world Lp(a)-enriched cohort. METHODS This post-hoc analysis of the GAELp(a) registry included 1861 adults with available apoB, Lp(a) expressed in nmol/L, and fasting triglycerides (TG) < 250 mg/dL. RW-apoB was calculated as: 11.65 × TG (mmol/L) + 0.215 × Lp(a) (nmol/L) + 0.736 × apoB (mg/dL). Reclassification was defined as the change in percentile rank between RW-apoB and measured apoB (Δ percentile). Analyses were stratified across five Lp(a) categories. A complementary analysis without TG truncation was performed in 1966 participants to evaluate the contribution of each RW-apoB component. RESULTS Mean apoB was 89.9 ± 27.6 mg/dL, whereas mean RW-apoB was 103.7 ± 36.3 mg/dL. Overall, 60.0% of participants were reclassified by ≥ 10 percentile points. In individuals with Lp(a) < 75 nmol/L, measured apoB slightly overestimated weighted atherogenic burden (median Δ percentile: -13.2). Conversely, apoB progressively underestimated weighted atherogenic burden with increasing Lp(a), reaching an RW-apoB/apoB ratio of 1.91 and median Δ percentile of +34.7 at Lp(a) ≥300 nmol/L. The reclassification pattern was virtually identical in the no-truncation analysis (60.0%), with Lp(a)-not TRL-identified as the primary driver of discordance between RW-apoB and measured apoB. CONCLUSIONS Conventional apoB substantially underestimated weighted atherogenic burden in individuals with elevated Lp(a), with discordance increasing at higher concentrations. These findings support particle-specific weighting approaches for apoB-based cardiovascular risk assessment.
No takes yet. Share an insight, caveat, or question.
Corral et al. (2026) conducted an observational in Elevated Lipoprotein(a) and atherogenic risk (n=1,861). Risk-weighted apoB vs. Measured apoB was evaluated on Reclassification by ≥ 10 percentile points between RW-apoB and measured apoB. Risk-weighted apoB reclassified 60.0% of participants by ≥ 10 percentile points compared to conventional apoB, showing that apoB underestimates risk at higher Lp(a) levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: